180 Life Sciences Corp Net Assets
180 Life Sciences Corp net assets. Based on the latest financial reports, 180 Life Sciences Corp (ATNF) has net assets worth $445.14 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.01 Billion) and total liabilities ($564.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of 180 Life Sciences Corp to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $445.14 Million |
| % of Total Assets | 44.1% |
| Annual Growth Rate | 112.94% |
| 5-Year Change | -69.45% |
| 10-Year Change | N/A |
| Growth Volatility | 192068.24 |
Net Assets of 180 Life Sciences Corp (2016–2024)
Net assets of 180 Life Sciences Corp from 2016 to 2024. This chart illustrates how 180 Life Sciences Corp's net assets have evolved over time, based on quarterly financial data. See ATNF net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for 180 Life Sciences Corp (2016–2024)
The table below shows the annual net assets of 180 Life Sciences Corp from 2016 to 2024. For live market cap and overall valuation, see 180 Life Sciences Corp (ATNF) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.25 Million | +7343.16% |
| 2023-12-31 | $-127.73K | -101.13% |
| 2022-12-31 | $11.34 Million | -71.15% |
| 2021-12-31 | $39.32 Million | +29.83% |
| 2020-12-31 | $30.29 Million | -21.48% |
| 2019-12-31 | $38.57 Million | +602.43% |
| 2018-12-31 | $-7.68 Million | -106.80% |
| 2017-12-31 | $112.83 Million | +515319.02% |
| 2016-12-31 | $21.89K | -- |
Equity Component Analysis
This analysis shows how different components contribute to 180 Life Sciences Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14152023400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
180 Life Sciences Corp Net Assets Breakdown (December 2024)
180 Life Sciences Corp net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $318.00 | 0.00% |
| Other Comprehensive Income | $-2.92 Million | -31.53% |
| Other Components | $153.69 Million | 1661.19% |
| Total Equity | $9.25 Million | 100.00% |
180 Life Sciences Corp Competitors by Market Cap
The table below lists competitors of 180 Life Sciences Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Loma Negra Compañía Industrial Argentina Sociedad Anónima
F:8LN
|
$1.08 Billion |
|
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
|
$1.08 Billion |
|
SVG Optronics Co Ltd
SHE:300331
|
$1.08 Billion |
|
Arendals Fossekompani ASA
OL:AFK
|
$1.08 Billion |
|
Smartgroup Corporation Ltd
AU:SIQ
|
$1.08 Billion |
|
Shandong Lukang Pharmaceutical Co Ltd
SHG:600789
|
$1.08 Billion |
|
Hunan Fazhan Industrial Co Ltd
SHE:000722
|
$1.08 Billion |
|
Oriental Holdings Bhd
KLSE:4006
|
$1.08 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 180 Life Sciences Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -127,733 to 9,251,911, a change of 9,379,644.
- Net loss of 6,168,177 reduced equity.
- Dividend payments of 8,011,510 reduced retained earnings.
- New share issuances of 2,572,789 increased equity.
- Other comprehensive income decreased equity by 15,579.
- Other factors increased equity by 21,002,121.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.17 Million | -66.67% |
| Dividends Paid | $8.01 Million | -86.59% |
| Share Issuances | $2.57 Million | +27.81% |
| Other Comprehensive Income | $-15.58K | -0.17% |
| Other Changes | $21.00 Million | +227.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares 180 Life Sciences Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.03x to 1.66x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $500.00 | $16.80 | x |
| 2018-12-31 | $-767.69 | $16.80 | x |
| 2019-12-31 | $1328.20 | $16.80 | x |
| 2020-12-31 | $1.67 | $16.80 | x |
| 2021-12-31 | $476.56 | $16.80 | x |
| 2022-12-31 | $113.42 | $16.80 | x |
| 2023-12-31 | $-0.34 | $16.80 | x |
| 2024-12-31 | $10.11 | $16.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 180 Life Sciences Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.38x
- Recent ROE (-66.67%) is below the historical average (-61.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -14.20% | 0.00% | 0.00x | 10.96x | $-5.30K |
| 2017 | 2.48% | 0.00% | 0.00x | 23.41x | $-376.24K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.73 Million |
| 2019 | -65.84% | 0.00% | 0.00x | 1.35x | $-29.25 Million |
| 2020 | -35.94% | 0.00% | 0.00x | 1.83x | $-13.91 Million |
| 2021 | -27.68% | 0.00% | 0.00x | 1.59x | $-14.82 Million |
| 2022 | -341.38% | 0.00% | 0.00x | 1.73x | $-39.86 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.92 Million |
| 2024 | -66.67% | 0.00% | 0.00x | 1.38x | $-7.09 Million |
Industry Comparison
This section compares 180 Life Sciences Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 180 Life Sciences Corp (ATNF) | $445.14 Million | -14.20% | 1.27x | $1.08 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About 180 Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more